Resource data sheet
DNA Bank Top

CS-RfA-ETV (#RDB08020)

Backbone vector plasmid of shRNA expressing lentivirus construct by Gateway(R) cloning with TetR-2A-Venus marker driven by EF-1 alpha promoter.


Drawn by SnapGene® software
Sequence information
(Assembled from experimentally sequenced data)		 GenBank Flat File Format open
SnapGene file download
Publication Unpublished bioresource
Test sheet Data Sheet open 
 
Clone info. Backbone vector plasmid of shRNA expressing lentivirus construct by Gateway(R) cloning with TetR-2A-Venus marker driven by EF-1 alpha promoter.
Comment pENTR4-H1tetOx1 (RDB07916) is used for construction of tetracyclin inducible shRNA expression vector. pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394) are popular choices for lentivirus packaging.
Selectable markers Ampicillin, Chloramphenicol, ccdB (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Growth remarks Use DB3.1, ccdB Survival or equivalent to amplify this clone. 30 degC is fine.
Depositor|Developer Miyoshi, Hiroyuki |

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link] 
Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.
Additional terms and conditions:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002).
Remarks Remember that you will be working with samples containing infectious virus.
Use Survival2 (Invitrogen) or equivalent to amplify this clone.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件 本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。
付加的使用条件：
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002).
備考 このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。
このクローンの増殖にはSurvival2 (Invitrogen)あるいは同等の宿主を使用してください。

Catalog # Resource name Shipping form Fee
RDB08020 CS-RfA-ETV Please contact us. JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Ordering instruction of plasmids [in Japanese] [in English]

How to cite this biological resource

Materials & Methods section:

The CS-RfA-ETV was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB08020).

Reference section:

Further references such as user reports and related articles (go to bottom)

References

Original, user report and related articles

reference Noura, M., Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
29 June 2023, PREPRINT (Version 1) available at Research Square https://doi.org/10.21203/rs.3.rs-3069900/v1 [Article]
user_report Noura, M., Induction of T-Cell Differentiation by KLF4 in T-Cell Acute Lymphoblastic Leukemia Cells Harboring Activating Mutation in NOTCH3. FASEB J. 39 (10): e70613 (2025). PMID 40354086. [PubMed] [Article] [RRC of NBRP]
user_report Watanabe, K., Inhibition of the galactosyltransferase C1GALT1 reduces osteosarcoma cell proliferation by interfering with ERK signaling and cell cycle progression. Cancer Gene Ther. 2024 Apr 15. doi: 10.1038/s41417-024-00773-9. Epub ahead of print. PMID 38622340. [PubMed] [Article] [RRC of NBRP]
user_report Matsui, Y., Chlorambucil-conjugated PI-polyamides (Chb-M'), a transcription inhibitor of RUNX family, has an anti-tumor activity against SHH-type medulloblastoma with p53 mutation. Biochem. Biophys. Res. Commun. 620: 150-157 (2022). PMID 35792512. [PubMed] [Article] [RRC of NBRP]
user_report Hattori, E.Y., A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice. Commun. Biol. 5 (1): 939 (2022). PMID 36085167. [PubMed] [Article] [RRC of NBRP]
user_report Noura, M., Pivotal role of DPYSL2A in KLF4-mediated monocytic differentiation of acute myeloid leukemia cells. Sci. Rep. 10 (1): 20245 (2020). PMID 33219287. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., RUNX transcription factors potentially control E-selectin expression in the bone marrow vascular niche in mice. Blood Adv. 2 (5): 509-515 (2018). PMID 29500219. [PubMed] [Article] [RRC of NBRP]
user_report Mitsuda, Y., RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Sci. Rep. 8 (1): 6423 (2018). PMID 29686309. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., Genetic regulation of the RUNX transcription factor family has antitumor effects. J. Clin. Invest. 127 (7): 2815-2828 (2017). PMID 28530640. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., Autonomous feedback loop of RUNX1-p53-CBFB in acute myeloid leukemia cells. Sci. Rep. 7 (1): 16604 (2017). PMID 29192243. [PubMed] [Article] [RRC of NBRP]
user_report Morita, K., Paradoxical enhancement of leukemogenesis in acute myeloid leukemia with moderately attenuated RUNX1 expressions. Blood Adv. 1: 1440-1451 (2017). PMID 29296785. [PubMed] [Article] [RRC of NBRP]